Back to Search Start Over

Impairment of RAD17 Functions by miR-506-3p as a Novel Synthetic Lethal Approach Targeting DNA Repair Pathways in Ovarian Cancer.

Authors :
Bagnoli M
Nicoletti R
Valitutti M
Rizzo A
Napoli A
Montalvão De Azevedo R
Tomassetti A
Mezzanzanica D
Source :
Frontiers in oncology [Front Oncol] 2022 Jul 18; Vol. 12, pp. 923508. Date of Electronic Publication: 2022 Jul 18 (Print Publication: 2022).
Publication Year :
2022

Abstract

Epithelial ovarian cancer (EOC) remains the most lethal gynecological cancer and development of chemo-resistance is a major factor in disease relapse. Homologous recombination (HR) is a critical pathway for DNA double strand break repair and its deficiency is associated to a better response to DNA damage-inducing agents. Strategies to inhibit HR-mediated DNA repair is a clinical need to improve patients' outcome. MicroRNA (miRNAs) affect most of cellular processes including response to cancer treatment. We previously showed that miR-506-3p targets RAD51 , an essential HR component. In this study we demonstrated that: i) another HR component, RAD17 , is also a direct target of miR-506-3p and that it is involved in mediating miR-506-3p phenotypic effects; ii) the impairment of miR-506-3p binding to RAD17 3' UTR reverted the miR-506-3p induced platinum sensitization; iii) miR-506-3p/RAD17 axis reduces the ability of EOC cell to sense DNA damage, abrogates the G2/M cell cycle checkpoint thus delaying the G2/M cell cycle arrest likely allowing the entry into mitosis of heavily DNA-damaged cells with a consequent mitotic catastrophe; iv) RAD17 expression, regulated by miR-506-3p, is synthetically lethal with inhibitors of cell cycle checkpoint kinases Chk1 and Wee1 in platinum resistant cell line. Overall miR-506-3p expression may recapitulate a BRCAness phenotype sensitizing EOC cells to chemotherapy and helping in selecting patients susceptible to DNA damaging drugs in combination with new small molecules targeting DNA-damage repair pathway.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Bagnoli, Nicoletti, Valitutti, Rizzo, Napoli, Montalvão De Azevedo, Tomassetti and Mezzanzanica.)

Details

Language :
English
ISSN :
2234-943X
Volume :
12
Database :
MEDLINE
Journal :
Frontiers in oncology
Publication Type :
Academic Journal
Accession number :
35924161
Full Text :
https://doi.org/10.3389/fonc.2022.923508